Amarin Corp Plc (AMRN)

[chas1232123]

TTE - " a median follow-up of 3ish years is very unlikely to get the HRs we got with a median follow-up of almost 5 years. "

Correct IMO. Good catch, I hadn't thought about that for STRENGTH (I don't worry much about Epanova.) If they're a little bit smart (and best to assume they are), they'll run STRENGTH to completion for several reasons, barring a really lucky statistical fluke in their favor. (There are ways to test for that.)

I expect EPA/DHA blends in sufficient doses have benefit, because fish-eating populations have reduced risk, and they get DHA. The science says you're right that the benefit will be substantially less than for V. Plus, Amarin presumably has applicable patent protection, not to mention a substantial head-start. Not a lot of reason to lose sleep about Epanova IMO.